SRG Clinical Trials: September 2026
ProCares - Clinical Suspicion NOW Re-Opened!
This study will enroll individuals 45 years of age or older with clinical suspicion of OR newly diagnosed cancer of the following types of cancer:
Biliary Tract, Colon, Esophagogastric Junction, Esophagus, Gallbladder, Head and Neck, Liver, Lung, Lymphatic System, Ovary, Pancreas, Rectum, Stomach
One time blood collection
No prior cancer history
Newly diagnosed cancer must be enrolled into the study within 45 days of diagnosis
Sanofi Crohn’s
Moderate to severe active Crohn’s
Unique, first in class, Nanobody therapeutic protein directed at TNF and OX40L (which plays a role in T-helper cell differentiation and maintenance)
SC injections Q2weeks
Biologic naïve and failed standard treatment OR failed at least 1 biologic/advanced therapy therapy class but not more than 3
No fistulizing disease, ostomy or ileoanal pouch or missing more than 2 entire segments of colon
No opiate use or cannabis use (even if for medical reasons)
Total study length: 52 weeks with additional Open Label Period of 104 weeks
CRC or Advanced Adenoma - Exact Sciences
Age 18 or older
Newly diagnosed CRC- not yet treated
Advanced Adenoma (>1cm remaining and biopsy proven) requiring follow up intervention
One time blood and stool collection
C-Diff- Vedanta
For patients with C-Diff who have had at least one prior occurrence of C-Diff within the last 6 months
VE303 is an oral, live biotherapeutic (taken in capsule form x 14 days) that will be administered following completion of a course of standard-of-care (SoC) antibiotics
Order initial stool testing via Quest if you think your patient may be a candidate
Crohn’s- Abivax
Moderate to severely active Crohn’s disease
ABX464 is an oral, novel anti-inflammatory drug
Documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids (CS), immunosuppressants (IS), biologic or biosimilar therapies, or JAK
Subjects may receive study drug for up to 100 weeks
Celiac-Chugai Daisy Study
Phase II Randomized, Double-Blind, Placebo-Controlled Study of DONQ52 in Active Treated Celiac Disease
DONQ52 – a humanized, multispecific IgG1 monoclonal antibody designed to bind HLA-DQ2.5–gluten peptide complexes and block gluten-dependent CD4+ T-cell activation, the initiating step of celiac disease pathology.
Adult (18–75) with diagnosed celiac disease
≥12 months on gluten-free diet
Ongoing GI symptoms
Total participation per patient is approximately 54 weeks
For more info about this study, please visit-
Janssen UC -NOW CLOSED as of 10SEP2026
Age 18 and older
Moderate to severe UC
Oral Anti IL-23
Prior failure or intolerance of conventional (5-ASA, oral corticosteroids, thiopurines) or advanced therapy (biologics or oral advanced therapies)- No failures of 3 or more advanced therapies
No prior exposure to biologic agent targeting IL-23p19 including guselkumab (Tremfya), mirikizumab (Omvoh), risankizumab (Skyrizi)
No stoma or ostomy
Total study length: 52 weeks with additional Open Label Period of 4 years
Caris Biorepository Blood Collection
Newly Diagnosed Pan-Cancer
· Age 18 and over
· Solid tumor cancer diagnosis within the past 3 months
· No prior cancer history (except non-melanoma skin cancer)
High Risk Genetic Pre-Disposition
· Age 18 and over
· Hereditary diagnosis of one of the following: Breast and Ovarian Cancer Syndrome, Lynch Syndrome, or Li-Fraumeni Syndrome- Must have lab confirmation
· No prior cancer history (except non-melanoma skin cancer)
GSK Balance Study IBS-D & IBS-M
Age 18-80
Moderate to severe IBS-D or IBS-M according to Rome IV criteria
Study medication is P2X3 homotrimeric receptor small molecule antagonist that may benefit IBS patients via modulation of neuronal hypersensitivity and potentially intestinal motility- Taken orally twice daily.
Must be up to date on all CRC screening and/or symptom investigation related to IBS symptoms
Having abdominal pain at least weekly
No IBD or Celiac disease
No bile salt diarrhea
No recreational marijuana use- medical use is permitted
BMI 18.5-35 kg/m2
Daily- multi entry electronic diary use required
Total study length up to 32 weeks